Artivion (NYSE:AORT) Price Target Cut to $48.00 by Analysts at Citizens Jmp

Artivion (NYSE:AORT) had its target price cut by Citizens Jmp from $53.00 to $48.00 in a report issued on Friday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Several other brokerages have also issued reports on AORT. Needham & Company LLC cut their target price on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday. Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research report on Thursday, March 5th. Canaccord Genuity Group cut their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, February 13th. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research report on Friday, April 10th. Finally, Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Artivion presently has an average rating of “Moderate Buy” and an average target price of $47.83.

Artivion Stock Down 28.4%

AORT opened at $25.36 on Friday. The company has a fifty day moving average price of $36.50 and a 200-day moving average price of $41.19. The firm has a market capitalization of $1.23 billion, a P/E ratio of 105.69 and a beta of 1.41. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. Artivion has a one year low of $19.16 and a one year high of $48.25.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $116.34 million during the quarter, compared to analyst estimates of $115.69 million. Artivion had a net margin of 2.55% and a return on equity of 7.21%. The business’s revenue for the quarter was up 17.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.01) EPS. Equities research analysts expect that Artivion will post 0.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Artivion news, insider John E. Davis sold 4,573 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $172,767.94. Following the completion of the sale, the insider directly owned 230,794 shares of the company’s stock, valued at $8,719,397.32. The trade was a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Lance A. Berry sold 6,316 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $238,618.48. Following the sale, the executive vice president owned 210,827 shares of the company’s stock, valued at approximately $7,965,044.06. This represents a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 133,043 shares of company stock valued at $4,977,158 over the last three months. 6.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Artivion

Several institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Royal Bank of Canada boosted its holdings in Artivion by 107.0% in the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after purchasing an additional 2,823 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after purchasing an additional 1,032 shares during the last quarter. Creative Planning boosted its holdings in Artivion by 5.6% in the second quarter. Creative Planning now owns 14,272 shares of the company’s stock worth $444,000 after purchasing an additional 753 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Artivion by 40.8% in the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after purchasing an additional 139,370 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Key Headlines Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Artivion reported Q1 2026 revenue of $116.3 million, up 18% year over year, and adjusted EPS of $0.08, topping analyst estimates. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: Adjusted EBITDA rose 26% to $22.1 million, showing improving profitability as the company grows. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: The FDA approved the NEXUS Aortic Arch System, a meaningful regulatory win that could expand Artivion’s addressable market and support future growth. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: Artivion exercised its option to acquire Endospan, which may strengthen its aortic disease portfolio over time. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Neutral Sentiment: The company guided 2026 revenue to $480 million-$496 million, which is near Wall Street expectations but not a major upside surprise. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Negative Sentiment: Despite the beat-and-raise style quarter, investors appear focused on the stock’s rich valuation and the lack of a major guidance surprise, contributing to the selloff. Why is Artivion stock plummeting today?
• Negative Sentiment: Citizens JMP and Needham both lowered price targets, which may have added to the negative sentiment even though both firms kept bullish ratings. Benzinga report on lowered price targets

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.